What are the latest femtech developments?

This blog post has been written by the person who has mapped the femtech market in a clean and beautiful presentation

The femtech industry reached $2.2B in investment in 2024, representing 32% year-over-year growth despite accounting for only 8.5% of total digital health funding. With 71% of femtech startups under six years old yet to reach Series A, the sector presents both significant opportunities and substantial challenges for entrepreneurs and investors entering this rapidly evolving market.

Major funding rounds from companies like Hims & Hers ($1B convertible debt), Future Family ($400M financing program), and ByHeart ($72M Series A) signal strong investor confidence in specific segments, while emerging areas like menopause care and AI-powered diagnostics are gaining unprecedented traction. And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Summary

The femtech market experienced significant growth in 2025 with $2.2B in total investment and major funding rounds across fertility, menopause care, and diagnostics sectors. North America maintains 65% of global investment while Asia-Pacific emerges as a high-growth region with strong government support and consumer adoption rates.

Market Segment	Investment Share	Key Players & Funding	Growth Drivers
Fertility & Reproductive Health	43.1% of total funding	Future Family ($400M), Cofertility ($7.25M), ReproNovo ($65M)	Strong commercial viability, clear regulatory pathways
Digital Health Platforms	Major funding rounds	Hims & Hers ($1B convertible debt), Commons Clinic ($26M Series B)	Platform integration, B2B opportunities
Menopause Care	7% of French startups	Growing investor interest, $27B employer cost opportunity	Increased awareness, corporate wellness programs
Diagnostics & AI	Emerging high-growth	PHASE Scientific ($34M), SpotitEarly ($20.3M), Visby Medical ($55M)	AI breakthroughs, at-home testing demand
Wearables & Monitoring	Technology-focused	Eli Health ($12M), Somnee ($10M)	Continuous monitoring, biosensor advances
Sexual Health	3.4% of clinical trials	Limited but growing investor interest	Consumer demand exceeds clinical validation
Geographic Markets	Global expansion	North America (65%), Europe (157% growth), Asia-Pacific (111 startups)	Regulatory support, healthcare infrastructure development

Get a Clear, Visual
Overview of This Market

We've already structured this market in a clean, concise, and up-to-date presentation. If you don't have time to waste digging around, download it now.

DOWNLOAD THE DECK

What major femtech startups have raised funding in 2025 so far, and how much did they raise?

The femtech sector witnessed substantial funding activity across multiple months in 2025, with several companies securing significant rounds to expand their platforms and geographic reach.

April 2025 delivered notable funding activity with Future Family securing a massive $400M financing program to expand fertility treatment access, while ByHeart raised $72M for baby formula manufacturing and distribution. Cofertility completed a $7.25M Series A for their egg freezing platform, and Fizimed raised €4M for international expansion of pelvic floor devices.

May 2025 saw even larger funding rounds, led by Hims & Hers' unprecedented $1B convertible debt offering for platform expansion. ReproNovo secured $65M in Series A funding for reproductive medicine treatments, PHASE Scientific raised $34M for urine-based diagnostics, and SpotitEarly completed a $20.3M round for AI-powered breast cancer detection technology.

June 2025 continued the momentum with Visby Medical raising $55M for their at-home STI testing platform, Commons Clinic securing $26M in Series B funding for multi-specialty women's health care, Eli Health completing a $12M Series A for instant hormone monitoring, and Somnee raising $10M for AI-powered sleep technology solutions.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Which femtech sub-sectors are currently seeing the most investor interest and commercial traction?

Fertility and reproductive health dominates femtech investment, capturing 43.1% of total funding over the past decade and maintaining its position as the most commercially viable segment.

This sector's strength stems from strong market demand, clear commercial viability with users willing to pay premium prices, and increasingly well-established regulatory pathways. Major companies like Future Family, Cofertility, and ReproNovo continue attracting significant investment due to proven business models and scalable technology platforms.

Menopause care represents the fastest-growing emerging segment, with 7% of French femtech startups now focused on this area—a significant 6-point increase from 2023. The sector's growth is driven by growing awareness of menopause's impact on quality of life and the substantial market opportunity, with menopause costing employers $27B annually in the US alone.

Mental health and sexual wellness are gaining traction as secondary growth areas, though they face unique market challenges. Sexual health represents only 3.4% of clinical trials despite strong consumer interest, while mental health solutions are expanding beyond traditional therapy models through integration with other health areas.

AI-powered diagnostics and digital health platforms are emerging as technology-focused high-growth areas, with companies like PHASE Scientific, SpotitEarly, and Visby Medical securing substantial funding for innovative diagnostic solutions that reduce time to diagnosis and improve accessibility.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What are the most promising geographic markets for femtech expansion in 2025 and going into 2026?

North America maintains its position as the dominant femtech market, capturing 65% of global investment due to mature healthcare infrastructure, strong venture capital ecosystems, and high healthcare spending with consumer willingness to pay premium prices.

Europe experienced remarkable 157% year-over-year growth in 2024, driven by progressive regulatory environments, strong government support for women's health initiatives, and growing recognition of the economic opportunity. Countries like France show particularly strong ecosystem development with 18% of femtech startups crossing the €1M revenue milestone in 2024.

Asia-Pacific emerges as the most dynamic growth market, with Southeast Asia representing particularly strong expansion potential. The region hosts 111 startups across multiple countries, with Singapore leading with 45 companies, supported by strong government backing and healthcare innovation initiatives.

The Asia-Pacific region demonstrates exceptional adoption potential, with 60% of consumers already using femtech products and 54% of non-users showing intention to adopt. This high engagement rate, combined with growing middle class populations and increasing smartphone penetration, creates substantial market expansion opportunities.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Which regulatory changes or government-backed initiatives in 2025 are helping or hindering femtech innovation globally?

Government initiatives increasingly support femtech innovation, with several major policy developments creating favorable regulatory environments for women's health technology companies.

The UAE launched its National Policy for Improving Women's Health in February 2024, while the US White House Initiative on Women's Health Research launched in November 2023 continues driving federal support for women's health innovation. The FDA's AI/ML guidance released in Q2 2025 significantly reduced perceived risks for patient-facing algorithms, enabling more companies to pursue AI-driven diagnostic and treatment solutions.

However, regulatory compliance remains a significant challenge for femtech companies. GDPR compliance issues are widespread among femtech apps, with many companies struggling to meet European data protection standards. The post-Dobbs environment in the United States creates additional data privacy concerns, particularly for reproductive health companies handling sensitive personal information.

The regulatory landscape requires femtech companies to navigate complex data protection standards across global markets, with varying requirements for clinical evidence and regulatory approval pathways. Companies expanding internationally must address evolving healthcare regulations that create compliance uncertainty, particularly in emerging markets with developing regulatory frameworks.

The Market Pitch
Without the Noise

We have prepared a clean, beautiful and structured summary of this market, ideal if you want to get smart fast, or present it clearly.

DOWNLOAD

What are the most successful product launches in femtech in 2025 in terms of user adoption, revenue, or clinical validation?

AI-powered diagnostic solutions lead successful product innovations in 2025, with breakthrough technologies significantly reducing diagnosis times and improving clinical outcomes for women's health conditions.

Product Category	Key Innovations	Clinical Impact & Adoption
AI-Powered Cervical Cancer Diagnosis	Advanced machine learning algorithms for rapid screening and diagnosis	Reduced diagnosis time from weeks to 20 minutes, improving early detection rates
Breast Cancer Screening Technology	Soft fabric alternatives to traditional compression mammography	Increased patient comfort and willingness to undergo regular screening
At-Home Hormone Testing	Instant hormone monitoring and tracking platforms	Enabled remote monitoring and personalized treatment management
Fertility Tracking Wearables	Advanced biosensor technology for improved accuracy	Higher precision in ovulation prediction and fertility management
Menopause Symptom Monitoring	Biometric data collection and analysis platforms	Personalized treatment recommendations and symptom management
Pelvic Floor Training Devices	Clinical validation and smart feedback systems	Improved patient outcomes and engagement in treatment programs
Digital Health Platform Integration	Comprehensive telemedicine and AI-powered insights	Streamlined care delivery and personalized treatment protocols

Which major M&A deals, IPOs, or exits have taken place in the femtech industry in 2025?

The femtech M&A landscape in 2025 shows limited but strategically significant activity, with most transactions occurring between venture-backed companies rather than traditional strategic acquisitions.

2024 femtech M&A activity revealed that 56% of transactions were venture-to-venture deals, indicating ongoing consolidation within the startup ecosystem. Notable transactions include In Women's Health acquiring FemHealth Insights in April 2025, and Willow's acquisition of British competitor Elvie representing significant sector consolidation in the maternal health technology space.

The IPO market remains challenging for femtech companies, with only 6 IPOs in digital health occurring globally in H1 2025. The continued sluggish IPO environment is expected to persist through the end of 2025, forcing most companies to pursue strategic acquisitions rather than public offerings for exit opportunities.

Most successful exits are occurring through strategic acquisitions rather than public market listings, as investors and companies adapt to challenging public market conditions. This trend suggests that femtech companies should focus on building strategic value for potential acquirers rather than preparing for immediate public market exits.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What B2B opportunities are emerging in femtech, such as employer health programs, insurance integrations, or clinical partnerships?

The employer benefits market represents one of the most significant B2B opportunities, with menopause-related costs alone costing employers $27B annually in the United States, creating substantial demand for workplace wellness solutions.

Corporate wellness programs increasingly include comprehensive women's health offerings such as menstrual health tracking and support, fertility benefits and family planning services, and menopause management programs. These initiatives address significant productivity and retention challenges while demonstrating clear ROI for employers investing in women's health benefits.

Healthcare system partnerships are expanding rapidly, with 23% of femtech collaborations now involving health systems. These partnerships focus on clinical integration opportunities, provider engagement to incorporate femtech solutions into standard treatment journeys, and clinical validation through evidence generation partnerships that demonstrate measurable health outcomes.

Insurance integrations are creating new revenue streams as coverage expands for femtech solutions, with insurers recognizing the potential for improved health outcomes and reduced long-term costs. B2B healthcare provider partnerships enable seamless integration into existing clinical workflows, improving adoption rates and patient engagement with digital health tools.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

What are the latest technological breakthroughs in femtech—like wearables, diagnostics, or AI-driven platforms—that are gaining traction in 2025?

Quantum computing applications for complex biological pathway analysis represent the most advanced technological frontier, enabling unprecedented understanding of women's health conditions and treatment optimization.

Agentic AI systems are providing autonomous health recommendations that go beyond simple tracking to deliver personalized treatment protocols. These advanced diagnostic platforms are dramatically shortening time to diagnosis for conditions like cervical cancer, reducing the process from weeks to minutes through machine learning algorithms.

Wearable and sensor technology innovations include continuous health monitoring devices that track multiple biomarkers simultaneously, smart textile integration for discrete health tracking that patients can wear throughout daily activities, and advanced biosensor technology for real-time hormone and fertility monitoring with clinical-grade accuracy.

Digital therapeutics are evolving from passive tracking applications to active treatment interventions, incorporating evidence-based therapeutic protocols, personalized treatment recommendations based on individual health data, and seamless integration with traditional medical care to create comprehensive treatment ecosystems.

We've Already Mapped This Market

From key figures to models and players, everything's already in one structured and beautiful deck, ready to download.

DOWNLOAD

Who are the key influencers, researchers, or thought leaders shaping the femtech space right now?

Ida Tin, founder of Clue, coined the term "femtech" and continues leading industry discourse through her insights on sustainable business models and clinical validation requirements for women's health technology companies.

Tania Boler of Elvie drives innovation in maternal health technology, focusing on evidence-based solutions that address real clinical needs rather than technology-first approaches. Karolina Löfqvist of Hormona leads hormone health innovation, particularly in developing clinical validation frameworks for digital therapeutics.

Industry organizations play crucial roles in ecosystem development, with the Femtech Association Asia leading regional market expansion and startup support across Southeast Asian markets. Women of Wearables maintains comprehensive industry leadership networks and facilitates connections between entrepreneurs, investors, and healthcare providers.

Femtech France drives European market development through policy advocacy and industry collaboration, while academic researchers increasingly focus on women's health disparities and technological solutions. These thought leaders emphasize the importance of clinical evidence, regulatory compliance, and sustainable business models over pure technology innovation.

If you want to build or invest on this market, you can download our latest market pitch deck here

What are the biggest pain points or underserved needs in women's health that femtech is trying to solve in the next 1 to 5 years?

Historical research gaps represent the most significant underserved areas, with endometriosis and chronic pain management remaining severely underfunded despite affecting millions of women globally.

Menopause research receives only 0.55% of total healthcare research funding, despite affecting half the global population and creating substantial quality of life and economic impacts. Sexual health innovations lag significantly behind market demand, with consumer interest far exceeding available clinical validation and treatment options.

Access and equity challenges create substantial barriers to femtech adoption, particularly in underserved geographic regions where healthcare infrastructure limitations prevent technology deployment. Cultural and societal barriers limit adoption in many markets, while cost and insurance coverage limitations restrict access even in developed healthcare systems.

Mental health integration remains underdeveloped, with most solutions focusing on individual conditions rather than comprehensive approaches that address the interconnected nature of women's physical and mental health. The industry must address these gaps through increased research funding, improved access models, and culturally appropriate solutions for diverse global markets.

Which femtech companies are demonstrating strong recurring revenue models or retention metrics that suggest long-term viability?

French femtech startups demonstrate particularly strong revenue performance, with 18% crossing the €1M revenue milestone in 2024 and 39% doubling revenue between 2023-2024, indicating robust business model validation.

Flo Health achieved unicorn status with a $1B valuation as Europe's first femtech unicorn, demonstrating the potential for subscription-based models in women's health tracking and education. Maven Clinic has built a successful B2B enterprise model serving employers and health systems with comprehensive women's health programs.

Hormona shows strong clinical validation and user retention through its hormone health optimization platform, combining clinical evidence with user engagement to create sustainable recurring revenue. Companies with hybrid B2B-B2C models are showing the strongest growth potential, leveraging both direct consumer payments and enterprise contracts.

Subscription and SaaS models prove most successful when combined with clinical validation and clear health outcomes, as users are willing to pay for solutions that demonstrably improve their health and quality of life. The most viable companies focus on specific health conditions with clear clinical pathways rather than general wellness tracking applications.

Curious about how money is made in this sector? Explore the most profitable business models in our sleek decks.

What risks or challenges should founders or investors entering the femtech space in 2025–2026 be most aware of?

Funding challenges represent the most immediate risk, with 71% of femtech startups under six years old yet to reach Series A, indicating significant capital raising difficulties compared to other digital health sectors.

Continued investor skepticism about market size and scalability creates substantial barriers to growth funding, despite the $1 trillion women's health gap representing clear market opportunity. Higher clinical validation requirements compared to other digital health sectors increase development costs and time to market, particularly for diagnostic and therapeutic applications.

Regulatory and compliance risks include complex data privacy requirements across global markets, with GDPR compliance issues widespread among femtech applications. Evolving healthcare regulations create compliance uncertainty, particularly for companies expanding internationally or developing AI-powered diagnostic tools.

Market competition and saturation challenges include investor perception of market saturation despite large unaddressed opportunities, difficulty differentiating in crowded sub-segments like fertility tracking, and the critical need for clear clinical and commercial validation to stand out from technology-focused competitors. Companies must focus on sustainable business models with proven clinical outcomes rather than purely technology-driven approaches.

Conclusion

The femtech industry in 2025 demonstrates both tremendous potential and significant execution challenges, with $2.2B in investment highlighting strong market validation while 71% of early-stage companies struggling to reach Series A funding rounds.

Success in this market requires focus on clinical validation, sustainable business models, and clear value demonstration to patients, providers, and payers rather than technology-first approaches that have characterized earlier industry development phases.

Sources

Read more blog posts

-FemTech Funding Landscape

-FemTech Business Models

-FemTech Investors Guide

-How Big is the FemTech Market

-FemTech Investment Opportunities

-FemTech New Technology

-FemTech Problems and Solutions

-Top FemTech Startups

-FemTech Trends Analysis

-Will FemTech Continue Growing

Back to blog